Sotrastaurin Acetate — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	7	—	—	2009-04
Leukemia	Phase2	Phase 2	1	—	—	Mar 12, 2015
Non-Hodgkin Lymphoma	Phase2	Phase 2	2	—	—	2011-11

Computedclinicaltrials

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GNA11 Mutation1
Mirdametinib + Sotrastaurin Acetate

Clinical trials

Trials with this intervention (7)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–7 of 7 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02273219	Trial of AEB071 in Combination With BYL719 in Patients With Melanoma	completed	Phase 1	30	Columbia UniversityOTHER	1	Aug 15, 2023	clinicaltrials
NCT00885196	A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis	completed	Phase 2	336